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Introduction
A characteristic feature of many cancer types is their
ability to metastasise to the skeleton. At the skeletal site of
metastatic invasion, the bone metabolism is dysregulated
and bone resorption or bone formation, or both, is upregu-
lated. Bone is the most common target site of metastatic
invasion in breast cancer [1]. This is of clinical importance
as metastatic bone disease is associated with increased
morbidity and excess mortality [2]. To initiate successful
preventive therapy it is thus imperative that the bone
metastases are detected early [3].
The diagnosis of bone metastases is usually performed
through bone scintigraphy. However, this technique is
invasive and is not sensitive enough for detection of the
very early stages of metastasis [4]. Biochemical markers
of bone turnover are noninvasive and may potentially
provide a more sensitive measure of metastatic skeletal
αD =  D-aspartyl peptide; αL = L-aspartyl peptide; βD =  D-isoaspartyl peptide; βL =  L-isoaspartyl peptide; Cr = creatinine; CTX = crosslinked
C-telopeptide of type I collagen; ELISA = enzyme-linked immunosorbent assay, HC+ = hypercalcemic with bone metastases; NC+ = normo-
calcemic with bone metastases; NC– = normocalcemic without radiological signs of bone metastases; SD = standard deviation.
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Abstract
Background Fragments of collagen type I containing the
epitope AHDGGR (CTX) are generated during bone resorption.
The aspartyl-glycine (DG) site within CTX is synthesised in the
L-aspartyl peptide (αL) form, but converts to the age-modified
forms L-isoaspartyl peptide (βL) and D-aspartyl peptide (αD) over
time. The purpose of the present study was to test the ability of
the various CTX forms to identify breast cancer patients with
bone metastases and to investigate whether such patients had
an altered CTX excretion pattern.
Methods In this cross-sectional study we compared CTX
excretion in healthy premenopausal and postmenopausal
women with CTX levels in patients with breast cancer. The
breast cancer cohort comprised eight hypercalcemic patients
with bone metastases (HC+), 100 normocalcemic patients
with bone metastases (NC+) and 15 normocalcemic patients
without bone metastases (NC–).
Results In HC+ patients and NC+ patients, the excretion of
αL CTX was highly increased compared with NC– patients
(P<0.01), with Z scores of 3.4 and 2.0, respectively. The
excretion of the age-modified forms (βL and αD CTX) was
less increased in HC+ patients and in NC+ patients as
compared with NC– patients, with Z scores of 2.2 and 1.0,
respectively, for βL CTX, and of 1.6 and 0.8, respectively, for
αD CTX.
Conclusion Assays for the various isoforms of CTX have
different sensitivities to identify patients affected by bone
metastases. The αL CTX isoform reflecting resorption of
young bone appeared to provide the best differentiation of
patients affected by breast cancer-induced bone
metastases. In conclusion, patients affected by metastatic
bone disease present an altered excretion pattern of CTX
isoforms.
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invasion, but clinical applications of the bone turnover
markers have not been thoroughly evaluated for such a
clinical role.
Degradation products derived from the α1 chain of type I
collagen (CTX) have been shown to provide a sensitive
and specific index of bone resorption [5,6]. Preliminary
studies have suggested that the CTX marker may be
applicable for monitoring skeletal metastases in breast
and prostate cancer patients [7,8]. The epitope recog-
nised in the CTX assays comprises the six residues
AHDGGR1209–1214 of the collagen type I C-terminal
telopeptide. The aspartyl-glycine site (DG) within this
epitope is susceptible to spontaneous nonenzymatic
rearrangement, as outlined in Fig.1.
CTX fragments derived from newly synthesised collagen
are of the native peptide form (L-aspartyl peptide [αL]),
where the aspartic acid residue (D1211) is on the L-enan-
tiomeric form and is linked to the glycine residue (G1212)
through a peptide bond. Collagen and CTX fragments will
rearrange with age to three age-modified forms: the iso-
merised form (L-isoaspartyl peptide [βL]), where the bond
between the aspartic acid and glycine residue goes
through the β-carboxyl group of the aspartyl residue; the
racemised form (D-aspartyl peptide [αD]), where the aspar-
tic acid (D1211) is on a D-enantiomeric form; and the iso-
merised and racemised form (D-isoaspartyl peptide [βD])
[9]. The relative accumulation of the three age-modified
forms is dependent on the balance between anabolic and
catabolic processes in bone, and pathologic situations
affecting these processes may thus also affect the relative
amounts of the four CTX forms [9–11].
It has been shown that in Paget’s disease of bone, a con-
dition characterised by a localised upregulation of bone
turnover, there is a significant increase in the ratio
between the native peptide form of CTX (αL) and the age-
modified forms (βL, D-isoaspartyl peptide and αD) [9]. The
use of CTX ratios may thus be indicative of the significant
decrease in the residence time and therefore the average
age of the resorbed bone collagen type I fragments in
Pagetic patients [9]. This indicates that perturbations in
the normally well-regulated process of bone turnover can
result in changes in the half-life of collagen type I within
the bone matrix. This in turn will result in increased
amounts of the newly synthesised αL CTX form in the cir-
culating pool of CTX fragments that is reflected in the ele-
vated ratios [9–11].
Metastatic bone cancer will also affect the balance
between the anabolic and catabolic processes at the local
Figure 1
Racemisation and isomerisation of CTX molecules. Reaction of the peptide backbone nitrogen with the aspartyl carboxyl residue can result in the
formation of a succinimide ring (a→b). This intermediate produces peptides and β-aspartyl peptides in both the D and L configurations. 
CTX, crosslinked C-telopeptide of type I collagen
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site of invasion. The measurement of CTX isoforms, and
the ratios between the native αL form and the age-modi-
fied forms of CTX, indicative of the age of the resorbed
collagen fragments, may thus provide clinical useful infor-
mation for diagnosing and monitoring bone metastasis
occurrence in cancer patients [11]. Such an application of
the CTX bone resorption markers may be especially rele-
vant for breast cancer patients, who have a high risk of
developing bone metastases.
In the present study, our aim was to assess the clinical
utility of the different CTX isoforms, as well as the ratios
between the isoforms, to detect breast cancer-induced
bone metastases. For this purpose, the urinary CTX iso-
forms αL, βL, and αD were quantified by immunoassay in
healthy premenopausal and postmenopausal women, and
in women affected with breast cancer either with or
without bone metastases.
Patients and methods
Study population
Urine samples were collected as the morning void from
24 healthy premenopausal women (age [mean±standard
deviation (SD)], 33.9±5.6 years) and 31 healthy post-
menopausal women (age 55.1±2.7 years). In addition,
123 female patients with histologically confirmed breast
cancer participated in the study. Eight patients were
hypercalcemic (serum calcium >2.7mmol/l, albumin cor-
rected), had radiologically confirmed bone metastases and
were 54.4±12.0 years of age (HC+ patients). One
hundred patients were normocalcemic (serum calcium
between 2.0 and 2.7mmol/l, albumin corrected), had radi-
ologically confirmed bone metastases and were
54.4±12.0 years of age (NC+ patients). Finally, 15 breast
cancer patients (54.5±12.3 years of age) were normocal-
cemic, had early stage (nonmetastatic) cancer but were
without radiological signs of bone metastases (NC–
patients).
Fifty per cent, 49% and 53% of subjects were pre-
menopausal in the HC+, NC+ and NC– patient groups,
respectively. There was no statistical difference between the
proportions of premenopausal women in the three groups.
The presence or absence of bone metastasis in patients
was determined by bone scintigraphy, and was confirmed
by conventional radiography (X-ray) as necessary. All
study subjects had serum creatinine <265µmol/l, and
received endocrine therapy and/or an anthracycline-con-
taining regimen. Some patients had additional radiother-
apy in the event of clinical symptoms (e.g. bone pain,
instability). The use of antineoplastic hormonal treatment
(20mg tamoxifen, 500mg aminoglutethimide, 500mg
provera) was allowed, but none of the patients were
receiving bisphosphonate therapy prior to entry into the
study. Informed, written consent was obtained from all par-
ticipants according to the Helsinki Declaration of 1975, as
revised in 1983. The study was approved by the local
human investigations committee.
Measurement of CTX isoforms by immunoassay
analysis
The α-CrossLaps radioimmunoassay [12] and the Cross-
Laps ELISA [13] are commercially available immuno-
assays specific for the native (αL) and isomerised (βL)
forms of CTX, respectively. The assays were performed as
recommended by the manufacturer (Nordic Bioscience
Diagnostics, Herlev, Denmark).
The αD-CTX ELISA is a competitive assay based on poly-
clonal rabbit antibodies for the αD form of CTX. The assay
has been described elsewhere [9]. All determinations of
urinary CTX were corrected for creatinine. The three CTX
assays were calibrated using synthetic CTX standards,
the concentration of which had been determined by analy-
sis of the total amino acid composition as described previ-
ously [14].
Statistical analysis
Biochemical data were compared between groups using
the Mann–Whitney U test (two-tailed). For all tests P≤0.05
was considered significant. The discriminatory power of the
different CTX isoforms or CTX ratios in distinguishing
groups from controls was assessed using T or Z scores
(i.e. number of SDs from the mean of the controls).
Results
The urinary excretion of all CTX forms was significantly
higher (P<0.001) in the postmenopausal group when
compared with the premenopausal women, with approxi-
mately 2.5-fold higher levels (Table 1). When ratios
between the newly synthesised αL form and the age-modi-
fied forms (βL and αD) were calculated, only minor and
nonsignificant differences were observed between pre-
menopausal and postmenopausal women. In patients with
breast cancer-induced bone metastases, the urinary
excretion of the newly synthesised αL CTX form was more
increased than the age-modified forms βL and αD. Com-
pared with NC– patients, the HC+ patients had a 3.4-fold
elevation in αL CTX and the NC+ patients had 2.2-fold
higher levels of αL CTX (P<0.01). The levels of αD CTX,
representing the oldest form of CTX, were increased
2.4-fold and 1.7-fold in HC+ patients and in NC+ patients
compared with NC– patients (Fig.2). The ratio between
the nonisomerised αL form and the racemised αD form of
CTX was consequently increased in NC+ patients and in
HC+ patients 2.2 and 1.5 times, respectively, when com-
pared with NC– patients, and increased 2.4 and
1.6 times, respectively, compared with postmenopausal
patients. However, these increases in the αL/αD ratio did
not reach statistical significance as evaluated by nonpara-
metric statistics.
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criminate between patients with bone metastases (HC+
patients and NC+ patients) and patients without bone
metastases (NC– patients) was assessed by Z-score
analysis using the mean and SD of the NC– patient group
(Fig.3). This analysis revealed that the αL CTX levels pro-
vided the best differentiation between patients with metas-
tases (HC+ patients and NC+ patients) and
nonmetastasised controls (Fig.3).
Although the αL/αD ratio displayed the highest mean
Z score, the urinary excretion of the αL CTX form still
appeared to have the best ability to identify patients
affected by bone metastases. Thus, 58% of patients
affected by bone metastases had significantly increased
αL CTX values (Z score >2) compared with breast cancer
patients without bone metastases (NC– patients) (Fig.3).
In comparison, 30% of patients affected by bone metas-
tases had αL/αD ratios more than 2 SDs above the normal
postmenopausal mean (Fig.3). In addition, whereas only
27% of patients affected by bone metastases had αL CTX
values below the mean of nonmetastasised controls (NC–
patients), 52% of these patients had αL/αD ratios below
this value (Fig.3).
Discussion
In the present study, the clinical utility of assays for the
various CTX forms in the assessment of breast cancer-
induced bone metastases was investigated.
The urinary concentration of all four CTX isoforms was ini-
tially measured in reference populations of healthy pre-
menopausal and postmenopausal women. The levels of
the three CTX isoforms αL, βL and αD were 2.3-fold to
2.7-fold higher in the postmenopausal women (Table 1), in
accordance with previous reports of CTX levels during the
menopause [15]. As all forms were elevated to the same
magnitude in postmenopause, the ratios between the
newly synthesised αL CTX form and the older βL and αD
CTX forms was not significantly different in pre-
menopausal and postmenopausal women. This indicates
that the average ‘age’ and thus the half-life of bone colla-
gen is similar in premenopausal and postmenopausal
women. In a study comprising larger cohorts, a small but
significant elevation in the αL/βL ratio was found, indicat-
ing that the net half-life of collagen is slightly decreased
after the menopause [16].
In breast cancer patients affected by bone metastases
(HC+ patients and NC+ patients), the levels of all CTX iso-
forms were elevated compared with healthy post-
menopausal controls or with NC– patients. The αL form
representing the degradation of newly formed bone was,
however, more elevated than the corresponding age-
related isoforms (Table 1). HC+ patients had a 3.4-fold ele-
vation in αL CTX levels, and a 2.2-fold elevation was seen
in NC+ patients, indicating that the more severe condition
in the HC+ patients is reflected by the αL CTX marker. The
least prominent elevation was seen for the αD CTX levels.
The  αL/αD CTX ratio reflecting the relative contents of
age-modified CTX forms was highly increased in HC+
patients (1.5-fold and 1.6-fold compared with NC–
patients and with postmenopausal patients, respectively)
and in NC+ patients (2.2-fold and 2.4-fold compared with
NC– patients and with postmenopausal patients). This
Breast Cancer Research    Vol 5 No 4 Cloos et al.
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Table 1
CTX levels in different groups
CTX isoform
Subjects αL CTX/Cr βL CTX/Cr αD CTX/Cr
Premenopausal patients Mean±standard deviation 3.65±1.41 5.74±3.46 1.75±0.94
Postmenopausal patients Mean±standard deviation 8.39±3.01 13. 6 ±3.9 3.62±1.08
P, U testa < 0.001 < 0.001 < 0.001
T scorea 3.4 2.3 2.0
Normocalcemic breast cancer Mean±standard deviation 10.2±6.23 12.7±11.3 4.73±4.14
patients without bone metastases P, U testb Not significant Not significant Not significant
Z scoreb 0.60 –0.23 1.03
Normocalcemic breast cancer Mean±standard deviation 22.6±24.8 24.6±18.4 7.95±9.11
patients with bone metastases P, U testc < 0.01 < 0.01 < 0.05
Z scorec 2.00 1.01 0.76
Hypercalcemic breast cancer Mean±standard deviation 35.1±27.8 38.0±23.7 11.3±10.2
patients with bone metastases P, U testc < 0.01 < 0.01 < 0.05
Z scorec 3.41 2.24 1.59
Concentrations are provided as µmol/mol. αD = D-aspartyl peptide; αL = L-aspartyl peptide; βL = L-isoaspartyl peptide; Cr, creatinine; 
CTX, crosslinked C-telopeptide of type I collagen. aVersus premenopausal patients. bVersus postmenopausal patients. cVersus normocalcemic
breast cancer patients without bone metastases.suggests that the age and thus the half-life of collagen
type I fragments generated by resorption is decreased in
the group of patients with bone metastases. Such a
decrease in collagen type I half-life is likely to reflect a sig-
nificant imbalance between anabolic and catabolic
processes at the focal area of metastatic invasion [11].
A similar imbalance is seen in some ‘high-turnover’ condi-
tions, including Paget’s disease [9,17]. In situations of
high bone turnover, the ‘aged’ bone matrix will rapidly be
replaced with a new matrix, leading to a lower residence
time (i.e. half-life) of bone collagen. More ‘young bone’ (as
reflected by the αL CTX levels) will be resorbed and the
relative content of age-modified forms will decrease. The
relative content of αL CTX is reflected in the CTX ratios,
providing an index of bone collagen half-life [9]. Among
the CTX ratios, the αL/αD ratio showed the most pro-
nounced elevation in the metastatic breast cancer
patients. This is in good agreement with kinetic studies of
the isomerisation and racemisation reactions, where it was
shown that the αD CTX form accumulates with the lowest
kinetic rate [9]. The αL/αD CTX ratio will thus be most
affected by changes of bone turnover processes influenc-
ing the half-life of collagen type I in the bone matrix. The
age-related  βL form accumulates with a slightly higher
kinetic rate than αD CTX [9]. This is also apparent from the
less pronounced increase in the αL/βL ratio compared with
the αL/αD ratio in metastatic patients.
When individual Z scores of CTX were calculated for the
metastatic breast cancer patients compared with the non-
Available online http://breast-cancer-research.com/content/5/4/R103
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Figure 2
Excretion of CTX isoforms in healthy premenopausal (Pre) and
postmenopausal controls (PM), and in breast cancer patients with
hypercalcemia and bone metastases (HC+), in normocalcemic
patients with bone metastases (NC+) and in normocalcemic patients
without bone metastases (NC–). Shaded areas indicate mean±2
standard deviations for healthy premenopausal women. Bars indicate
medians. αD = D-aspartyl peptide; αL = L-aspartyl peptide; βL = L-
isoaspartyl peptide; CTX, crosslinked C-telopeptide of type I collagen.
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Figure 3
The discriminatory power of CTX markers and CTX ratios to identify
breast cancer-induced bone metastases. Open circles, individual
Z scores for hypercalcemic patients with bone metastases (HC+) and
normocalcemic patients with bone metastases (NC+). Z scores are
calculated using the mean and standard deviation of normocalcemic
breast cancer controls without bone metastases. αD = D-aspartyl
peptide; αL = L-aspartyl peptide; βL = L-isoaspartyl peptide; CTX,
crosslinked C-telopeptide of type I collagen.
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27% 22% 36% 72% 52%metastatic patients, the αL CTX form and the αL/αD CTX
ratio showed the highest average increases in accordance
with the ability of the αL CTX levels and the αL/αD CTX
ratio to most sensitively reflect alterations in the balance
between the anabolic and catabolic processes of bone
turnover (Fig.3). αL CTX levels alone showed a significant
elevation in 58% of the metastatic patients, which proba-
bly reflects an increased bone turnover (increased resorp-
tion + increased formation) as an important feature in the
majority of bone metastatic patients. For the βL and αD
CTX markers, respectively, 47 and 48% of the metastatic
patients had levels 2 SDs above the reference level of
nonmetastasised controls (Fig.3).
The present data suggest that the levels of αL CTX are
most affected by the altered bone turnover associated
with metastatic invasion of bone. The fact that only 58% of
patients affected by bone metastases (as determined by
radiology) have increased levels of αL CTX indicates a
rather low sensitivity of bone resorption markers to identify
bone metastases. Several issues are relevant for the inter-
pretation of this result. It may be speculated that different
stages of the bone metastases process show varying
release of αL CTX. Furthermore, the difference may be
related to differences between sclerotic and lytic bone
metastases. In this context it is noteworthy that some
patients who have not been classified as having bone
metastases by radiological methods have αL CTX values
increased more than 2 SDs above the normal mean.
High levels of αL CTX are indicative of an increased bone
resorption. In the clinical management of individual
patients affected with breast cancer, an increased αL CTX
value may indicate the presence of bone metastases and
will call for a closer clinical evaluation of the patient and/or
initiation of preventive therapy (e.g. bisphosphonates).
The study has some limitations. Most patients received
antineoplastic hormonal treatment (20mg tamoxifen,
500mg aminoglutethimide, 500mg provera). This treat-
ment may potentially reduce bone resorption, thereby
influencing CTX levels. It may thus be a confounding
factor in the analysis. In spite of this treatment, however,
patients affected by bone metastases had highly
increased marker values compared with healthy controls.
This indicates that the increase in markers is related to
metastatic invasion of bone and is reflected in systemic
marker levels regardless of the potential antiresorptive
effects of antineoplastic therapy.
Conclusion
Assays for the various age-related isoforms of CTX have
different sensitivities to identify patients affected by bone
metastases. The αL CTX isoform reflecting resorption of
young bone appeared to provide the best differentiation of
patients affected by breast cancer-induced bone metas-
tases. Further studies are needed to investigate the utility
of this marker in the early detection of bone metastases
and for assessing treatment efficacy. Such studies should
correlate marker values with metastasis type (lytic, scle-
rotic, mixed) and with the volume of bone affected by
metastases.
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